View
227
Download
0
Category
Preview:
Citation preview
8/14/2019 Heparin LMWH Thrombin
1/71
Interventional Lecture Series
Thrombin/LMWH/Heparin
8/14/2019 Heparin LMWH Thrombin
2/71
8/14/2019 Heparin LMWH Thrombin
3/71
8/14/2019 Heparin LMWH Thrombin
4/71
Heparin and LMWH
8/14/2019 Heparin LMWH Thrombin
5/71
8/14/2019 Heparin LMWH Thrombin
6/71
Given Vial ~ 2/3molecules arebiologically inert
To be biologicallyactive needs 5
repititions of thepentasaccharide ->this unit binds theantithrombin
No direct affinity tothrombin but inhibitsformation of thrombin
8/14/2019 Heparin LMWH Thrombin
7/71
Major Minor
Procoagulant
8/14/2019 Heparin LMWH Thrombin
8/71
Heparin bindstoAntithrombincausing aconformational
change w/amplifies itsanti-Xa activity
To inactivatethrombin,heparin mustsimultaneouslybind to AT andThrombin thereforemolecule lengthis important
Only exert effecton antithrombinand inhibit Xawithout action onthrombin
8/14/2019 Heparin LMWH Thrombin
9/71
Antithrombin Serine Protease Inhibitor
Large size does not penetrate clot well
Responsible for anticoagulant effect of all heparins (UFH, LMWH, Pentasaccarides)
Inhibits Xa
Affinity for Xa is increased 2000x by pentasaccaride sequence of heparin
Congenital and Acquired deficiencies Liver disease Nephrotic syndrome Continuous heparin therapy (50-60% decrease)
8/14/2019 Heparin LMWH Thrombin
10/71
8/14/2019 Heparin LMWH Thrombin
11/71
8/14/2019 Heparin LMWH Thrombin
12/71
8/14/2019 Heparin LMWH Thrombin
13/71
8/14/2019 Heparin LMWH Thrombin
14/71
Guidelines
For patients not receiving IIb/IIIa 70-100U/Kg bolus, check ACT after 5 minutes Achieve Target ACT 250-300 Hemotec Achieve Target ACT 300-350 Hemochron ACT< 250 addtl 2K-5K bolus
For patients receiving IIb/IIIa 50-70U/Kg bolus, check ACT after 5 minutes Achieve Target ACT 200
8/14/2019 Heparin LMWH Thrombin
15/71
8/14/2019 Heparin LMWH Thrombin
16/71
8/14/2019 Heparin LMWH Thrombin
17/71
8/14/2019 Heparin LMWH Thrombin
18/71
8/14/2019 Heparin LMWH Thrombin
19/71
8/14/2019 Heparin LMWH Thrombin
20/71
Early Trials
Overall improved clinical outcomes with increased minor bleeding complications
8/14/2019 Heparin LMWH Thrombin
21/71
8/14/2019 Heparin LMWH Thrombin
22/71
8/14/2019 Heparin LMWH Thrombin
23/71
8/14/2019 Heparin LMWH Thrombin
24/71
8/14/2019 Heparin LMWH Thrombin
25/71
UFH according tocurrent guidelineswith ACTmonitoring
8/14/2019 Heparin LMWH Thrombin
26/71
8/14/2019 Heparin LMWH Thrombin
27/71
Guidelines Dosing of Lovenox depends on the last SQ dose given
(After administration of 2 SQ doses!!) Last SQ dose 8hrs or less -> no addtl dosing SQ 8-12 hours -> 0.3mg/kg IV Greater than 12 hours -> 0.75 to 1mg/kg IV or SQ can be given
Xa Level (reasonable if Weight >150Kg) 0.8 to 1.8 IU/ml is recommended
Renal Dosing CrCl 30-60ml/kg 0.75 mg/kg SQ bid CrCl
8/14/2019 Heparin LMWH Thrombin
28/71
Pentasaccarides
8/14/2019 Heparin LMWH Thrombin
29/71
Fondaparinux / Arixtra
After 2.5mg dose therapeutic level achievedafter 2.5 hours !!!Oasis dosing and PE dosing are different
Therefore Dr. Kern prescribes the wrong dose all thetime
Renal Clearance 50% less renal clearance for CrCL 30ml/min
life 17-21 hours
8/14/2019 Heparin LMWH Thrombin
30/71
8/14/2019 Heparin LMWH Thrombin
31/71
8/14/2019 Heparin LMWH Thrombin
32/71
8/14/2019 Heparin LMWH Thrombin
33/71
Direct Thrombin Inhibitors in
PCI
8/14/2019 Heparin LMWH Thrombin
34/71
Early Angioplasty Trials
HAT (Hirudin)
No significantlong termbenefit for Hirudindespitesomewhatlower cardiacevent rates
8/14/2019 Heparin LMWH Thrombin
35/71
Early Angioplasty Trials
Bivalirudin Trial
8/14/2019 Heparin LMWH Thrombin
36/71
Early Angioplasty Trials
8/14/2019 Heparin LMWH Thrombin
37/71
Contemporary PCI - Cachet
8/14/2019 Heparin LMWH Thrombin
38/71
Contemporary PCI - Cachet
8/14/2019 Heparin LMWH Thrombin
39/71
Contemporary PCI REPLACE-1
8/14/2019 Heparin LMWH Thrombin
40/71
Contemporary PCI REPLACE-1
8/14/2019 Heparin LMWH Thrombin
41/71
Contemporary PCI REPLACE-1
8/14/2019 Heparin LMWH Thrombin
42/71
Contemporary PCI REPLACE-1
8/14/2019 Heparin LMWH Thrombin
43/71
Contemporary PCI
Main limitation of previous studies is rather small overall size.
Setup for REPLACE -2: 6,000 patient,large clinical trial on the use and effects of bivalirudin in a contemporary PCI andstenting.
8/14/2019 Heparin LMWH Thrombin
44/71
Replace - 2
8/14/2019 Heparin LMWH Thrombin
45/71
Replace - 2 Claim made by
study thatbivalirudin issuperior toheparin
Claim madebased onEpistent/Espritdata publishedearlier
NOrandomizedarm for heparinalone in thisstudy
8/14/2019 Heparin LMWH Thrombin
46/71
Replace - 2
8/14/2019 Heparin LMWH Thrombin
47/71
Replace - 2
8/14/2019 Heparin LMWH Thrombin
48/71
Replace - 2
8/14/2019 Heparin LMWH Thrombin
49/71
Replace - 2
8/14/2019 Heparin LMWH Thrombin
50/71
Replace - 2
8/14/2019 Heparin LMWH Thrombin
51/71
Replace - 2
Bleeding major driver of bivalirudin benefit
8/14/2019 Heparin LMWH Thrombin
52/71
Replace - 2
8/14/2019 Heparin LMWH Thrombin
53/71
Replace - 2
Major bleeding correlates with death
8/14/2019 Heparin LMWH Thrombin
54/71
Replace - 2
8/14/2019 Heparin LMWH Thrombin
55/71
Acuity Trial
8/14/2019 Heparin LMWH Thrombin
56/71
ACUITY Trial
8/14/2019 Heparin LMWH Thrombin
57/71
ACUITY Trial
8/14/2019 Heparin LMWH Thrombin
58/71
ACUITY Trial
8/14/2019 Heparin LMWH Thrombin
59/71
ACUITY Trial
8/14/2019 Heparin LMWH Thrombin
60/71
ACUITY Trial The hypothesis of this
randomization indicate thatcompared to a routineupstream use of a IIb/IIIainhibitor in all patients withACS, withholding the upfronttherapy with IIb/IIIa for adeferred administration in thecath lab only to those patientsundergoing PCI with result in: similar 30-day rates of death,
MI, or unplannedrevascularization for ischemia reduced bleeding, or major
bleeding complication improved cost effectiveness
8/14/2019 Heparin LMWH Thrombin
61/71
ACUITY Trial
8/14/2019 Heparin LMWH Thrombin
62/71
ACUITY Trial
8/14/2019 Heparin LMWH Thrombin
63/71
H i I d d
8/14/2019 Heparin LMWH Thrombin
64/71
Heparin InducedThrombocytopenia
HIT II Platelet drop >50% or 150K Usually seen 5 days after start of heparin Unexplained thrombosis (increases risk 40x)
50% risk of thrombosis @ 30 days Presence of Anti-Heparin PS4 complex, (NAP-2 receptor) Occurs with Heparin, Lovenox (no report of arixtra even though antibodies to PS4
have been discovered in patients) Qualitative and functional assay
Differentiate from type I HIT 15% of patients receiving heparin transient decrease in platelet count (down to 50% normal) without any further
symptoms secondary to platelet sequesteration. Platelet counts recover even if heparin continues to be administered. Platelet counts rarely fall below 100,000. Type I HIT is not due to an auto-immune disorder (as Type II is).
8/14/2019 Heparin LMWH Thrombin
65/71
8/14/2019 Heparin LMWH Thrombin
66/71
8/14/2019 Heparin LMWH Thrombin
67/71
8/14/2019 Heparin LMWH Thrombin
68/71
8/14/2019 Heparin LMWH Thrombin
69/71
8/14/2019 Heparin LMWH Thrombin
70/71
Therapeutic Options
LMWH high cross-reactivity Warfarin initially can induce skin necrosis ASA is inadequate Options remain:
Lepirudin (limited by significant anaphylaxis if agent is used more than
once) Argatroban Bivalirudin
Treatment should be continued for at least 4weeks Coumadin may be added after Plateletcounts recovered to >150K
8/14/2019 Heparin LMWH Thrombin
71/71
Questions
Thank you for your attention andparticipation
Recommended